
Chemicals & Agrochemicals · BSE
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts designed to enhance soil and crop health. The company specializes in pesticide formulations and supplies bulk products to leading Indian agrochemical players as well as multinational corporations (MNCs). Mahamaya imports global research-based molecules, registers them with the Central Insecticides Board, and markets both technical and value-added formulations. The company has invested significantly in global registrations and currently exports to markets such as the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey. Its portfolio spans bulk formulations, technical grade molecules, branded products, and export-focused formulations.
Price Band
₹108 – ₹114
Issue Size
₹70.44 Cr
Lot Size
1200 shares
GMP
Est. Listing
₹114
at current GMP
Subscribed
1.71x
overall
Open
11 Nov 2025
Close
13 Nov 2025
Allotment
14 Nov 2025
Refund
15 Nov 2025
Demat Credit
16 Nov 2025
Listing
18 Nov 2025
Last updated: 19 Oct 2026
Current Premium
Issue Price (Upper)
₹114
Band: ₹108 – ₹114
Estimated Listing Price
₹114
Upper price + GMP
Lot Size
1200 shares
Min investment ₹1,36,800
Estimated Profit / Lot
₹0
1200 × ₹0
Grey Market Premium trend
—
▲ 0 today
Updated less than a minute ago
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | — | 0.0% | ₹114 |
| 30 Oct 2026 | — | 0.0% | ₹114 |
| 29 Oct 2026 | — | 0.0% | ₹114 |
GMP is unofficial market data. Not a guarantee of listing performance.
Mahamaya Lifesciences Limited is bringing an initial public offering (IPO) in the Chemicals & Agrochemicals sector with an aggregate issue size of ₹70.44 Crores. The shares are offered at a price band of ₹108 to ₹114 per equity share on BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Following the close of bidding on 2025-11-13, the basis of allotment is scheduled to be finalized on 2025-11-14. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Kfin Technologies Limited) or the BSE allotment checking window.
The latest grey market premium for Mahamaya Lifesciences Limited IPO is ₹0, which indicates an expected listing price of ₹114.
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.